Maury Raycroft
Stock Analyst at Jefferies
(0.40)
# 3,941
Out of 4,784 analysts
56
Total ratings
17.07%
Success rate
-23.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $5.52 | +860.14% | 2 | Mar 11, 2025 | |
| CMRX Chimerix | Downgrades: Hold | $10 → $8.5 | $8.50 | - | 2 | Mar 5, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $1.99 | +302.01% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.82 | +265.85% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.30 | +204.35% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.52 | +294.74% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $0.92 | +1,747.42% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $1.47 | +1,192.52% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $1.99 | +653.77% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $19.99 | +95.10% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.92 | +552.17% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.48 | +1,454.05% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.77 | +1,842.75% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.86 | +39.95% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $0.23 | +3,811.34% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $26.63 | -77.47% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $13.82 | +442.69% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $268.46 | -13.58% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $2.93 | +275.43% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $9.77 | +176.36% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.44 | +247.22% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $10.24 | +368.75% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $7.26 | +395.87% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.32 | +2,330.56% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $36.99 | +364.99% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $1.61 | +2,819.25% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $0.78 | +5,020.98% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.92 | +4,574.80% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $8.07 | +420.45% | 3 | Nov 1, 2017 |
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $5.52
Upside: +860.14%
Chimerix
Mar 5, 2025
Downgrades: Hold
Price Target: $10 → $8.5
Current: $8.50
Upside: -
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.99
Upside: +302.01%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.82
Upside: +265.85%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.30
Upside: +204.35%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.52
Upside: +294.74%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $0.92
Upside: +1,747.42%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $1.47
Upside: +1,192.52%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $1.99
Upside: +653.77%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $19.99
Upside: +95.10%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.92
Upside: +552.17%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.48
Upside: +1,454.05%
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $0.77
Upside: +1,842.75%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.86
Upside: +39.95%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $0.23
Upside: +3,811.34%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $26.63
Upside: -77.47%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $13.82
Upside: +442.69%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $268.46
Upside: -13.58%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $2.93
Upside: +275.43%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $9.77
Upside: +176.36%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.44
Upside: +247.22%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $10.24
Upside: +368.75%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $7.26
Upside: +395.87%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.32
Upside: +2,330.56%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $36.99
Upside: +364.99%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $1.61
Upside: +2,819.25%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $0.78
Upside: +5,020.98%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.92
Upside: +4,574.80%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $8.07
Upside: +420.45%